metastatic sites) logistic regression analyses were used. Results: Overall, 2743 patients were included. Median overall survival was 2.2 months for all patients; for those receiving FOLFIRINOX (16.5%) 8.2 months, gemcitabinnab-paclitaxel (2.1%) 6.7 months, gemcitabin-monotherapy (7.3%) 4.2 months and no chemotherapy (72.6%) 1.5 months (p<0.001). Thirty-day mortality was 25.0% (n=685) and 90-day 59.4% (n=1629). All biomarkers predicted 90-day and 30-to-90-day mortality in univariable analysis. CA19.9 (p=0.005), albumin (p=0.001), CRP (p=0.019), LDH (p<0.001), GPS (p=0.001) and mGPS (p<0.001) predicted 90-day mortality after adjustment for patient and tumor characteristics. For 30-to-90-day mortality this was CA19.9, LDH, GPS and mGPS (see Table ). In the subgroup of patients receiving palliative chemotherapy, all biomarkers predicted 90-day mortality (n=150; 20.1%) in univariable analysis. CA19.9 (p=0.03), GPS score of 2 (p=0.02) and mGPS score of 2 (p=0.03) predicted 90-day mortality after adjustment. Discussion: This study showed that CA19.9, albumin, CRP, LDH, GPS, and mGPS could help to identify mPC patients with very poor survival. Albumin and CRP predicted 90-day mortality and not 30-to-90-day mortality, whereas CA19.9 only predicted 30-to-90-day mortality. These findings can assist in shared decision-making, especially when feasibility of palliative chemotherapy administration is doubtful. Moreover, it can be used in future prognostic modelling studies and for stratification in clinical trials.

The ImageJ model can be used on processed digital mammograms. The measurements strongly correlate with Cumulus, the BI-RADS density classification, and breast cancer risk factors.

Comparison of adjuvant gemcitabine and capeci-tabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389: 1011-1024. 3. Conroy T, Hammel P, Hebbar M, et al. Canadian Cancer Trials Group and the Unicancer-GI -PRO-DIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.